The diagnosis of endometriosis and fertility disorders is difficult; therefore, it is necessary to look for reliable biomarkers. Analysis of the molecular status of fibronectin as a key player in repair and wound healing processes, as well as in coagulation and fibrinolysis pathways, is justified. ELISA and SDS-agarose immunoblotting were applied to determine the fibronectin concentration and presence and occurrence of soluble FN-fibrin complexes in the blood plasma of women with endometriosis (n = 38), fertility disorders (n = 28) and the healthy group (n = 25). The concentration of fibronectin in the blood plasma of women with endometriosis (292.61 ± 96.17 mg/L) and fertility disorders (287.53 ± 122.68 mg/L) was significantly higher than in the normal group (226.55 ± 91.98 mg/L). The presence of FN-fibrin complexes of 750, 1000, 1300, 1600 and 1900 kDa in the plasma of women with endometriosis and fertility disorders was shown. The presence of FN-fibrin complexes with a molecular mass of more than 1300 kDa in women with endometriosis and infertility and the complete absence of these complexes in healthy women may indicate an increased and chronic activation of coagulation mechanisms in these patients. The presence of complexes of high molecular mass may be one of the biomarkers of fertility disorders in women.
The loss of immune tolerance to fetal antigens may result in reproductive failure. The downregulated number and activity of T regulatory lymphocytes, which are critical for the establishment of immune tolerance to fetal antigens, during pregnancy may lead to miscarriage. The adoptive transfer of Tregs prevents fetal loss in abortion-prone mice. Recently, we demonstrated that the administration of tregitopes, which are short peptides found in human and mouse immunoglobulins (IgGs), decreased the incidence of abortions in female CBA/J mice mated with DBA/2J mice. Here, two non-IgG source peptides (SGS and LKD) that can potentially bind to the major histocompatibility complex II (MHC II) with high affinity and induce Treg expansion were designed in silico. The immune dysregulation-induced pregnancy failure mouse model was used to evaluate the effect of SGS and LKD on immune response and pregnancy outcome. The fetal death rate in the SGS-treated group was lower than that in the phosphate-buffered saline-treated group. SGS and LKD upregulated the splenic pool of Tregs and modulated the T-helper cell (Th1)/Th2-related cytokine response at the preimplantation stage. Additionally, SGS and LKD downregulated the expression of CD80 and MHC class II molecules in splenic CD11c+ antigen-presenting cells. Thus, SGS treatment can result in beneficial pregnancy outcomes. Additionally, SGS peptide-mediated immunomodulation can be a potential therapeutic strategy for immune dysregulation-induced pregnancy failure.
Immunological dysregulation may be involved in pregnancy loss. Regulatory T (Treg) and B (Breg) cells, together with interleukin-35 (IL-35), contribute to maternal-fetal tolerance. This study investigated peripheral regulatory cell populations in healthy pregnancy and recurrent spontaneous pregnancy loss (RPL), focusing on the potential relationships between regulatory B and T cells within a coordinated immunoregulatory network associated with immune tolerance during pregnancy. Peripheral blood samples were collected from healthy pregnant women and women following spontaneous miscarriage. Frequencies of Breg subsets, including B10 cells, immature B cells, and plasmablasts, as well as the proportions of cells expressing IL-35, IL-10, PD-L1, and PD-L2, were analyzed. Tregs and the regulatory T-cell subsets iTr35, Tr1, and Th3 were also examined for the expression of IL-35, IL-10, TGF-β, and PD-1. In addition, correlations between Treg and Breg populations were assessed. Miscarriage was associated with significantly reduced frequencies of IL-35+ immature B cells, IL-35+ B10-like cells, IL-35+ plasmablasts, IL-35+ Tregs, and iTr35 cells. A negative correlation was observed between PD-L1-expressing B10-like cells and the frequencies of Treg and Th3 cells. Notably, this study is the first to demonstrate a positive correlation between IL-35-producing Bregs and iTr35 cells in healthy pregnancy. These findings suggest that the observed relationships between peripheral regulatory B- and T-cell populations and IL-35-associated regulatory subsets may be relevant to immune regulation during pregnancy. The iTr35/IL-35+ Breg ratios showed potential discriminatory value between healthy pregnancy and pregnancy loss groups and may warrant further investigation as candidate markers in prospective studies.